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Benzocaine as a main active substance in the Herplex gel, Galex d.d. used for healing 
of fever blister is treated as a local anaesthetic. According to European Pharmacopoeia 
titration method for determination of benzocaine is applied in the pharmaceutical 
industry. However its degradation products (determination of p-nitrobenzoic acid 
ethylester (EPNB) and p-aminobenzoic acid (PABA)) are not described 
in pharmacopoeias (neither Ph. Eur nor USP). 
 
Two high performance liquid chromatography methods with UV detection were 
developed for determination of benzocaine and both degradation products 
(p-nitrobenzoic acid ethylester and p-aminobenzoic acid). Procedures for extraction 
of these active from the Herplex gel were developed too. 
 
Optimum results were obtained with a column Eclipse XDB – C 18 (4.6 x 150 mm, 
5 µm) and a mobile phase comprising glacial acetic acid solution (10%, v/v) 
and methanol. Injection volume was set to 10 µml and temperature to 40 ˚C. Other 
conditions used in methods varied. The first method for benzocaine and EPNB was set 
to flow rate 2 ml/min, detection time 30 min and mobile phase was carried as a gradient 
profile programme whereas the second method for PABA was set to flow rate 1 ml/min, 
detection time 10 min and glacial acetic acid solution and methanol in the rate 
of 90 : 10%, v/v. Both methods were validated (specificity, linearity, accuracy 
and precision) at single wavelength 258 nm. Limit of detection and limit 
of quantification values for degradation products EPNB and PABA were determined. 
For EPNB LOD value 0.3404 µg/ml and LOQ value 1.0315 µg/ml were found 
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c  mass concentration (µg/ml) 
CV  coefficient of variation 
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DNA  deoxyribonucleic acid 
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HPLC  high performance liquid chromatography 
ICH  International Conference on Harmonization 
LOD  limit of detection (µg/ml) 
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2
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UV  ultraviolet 
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Benzocaine, 4-aminobenzoic acid ethylester or p-aminobenzoic acid ethylester 
(C9H11NO2) is a white, crystalline powder or in form of colourless crystals, very slightly 
soluble in water, freely soluble in alcohol 96% and in ether. Its molar mass 
is 165.189 g/mol [1, 2, 3]. Its monograph can be found in Ph. Eur 5
th
 Ed., USP XXII 




Benzocaine belongs to drug category of anaesthetics, antipruritics and local anaesthetics 
(ester type). Benzocaine is included in many pharmaceutical topical preparations (rarely 
cosmetics) [4] commonly used in the treatment of wound, pains, itches caused 
by conditions such as sunburn or other minor burns, insect bites or stings, minor cuts 
and scratches but also in the treatment of larynx, buccal affections, nasal cavity, 
respiratory tract or trachea, otitis externa, dermatitis, haemorrhoids pruritus, urinary 
tract or vagina and rectum [5]. 
 
Mechanism of benzocaine action is based on the binding to sodium channel 
and reversibly stabilization of the neuronal membrane which decreases its permeability 
to sodium ions since pain is caused by the stimulation of nerve endings [5]. When 
the nerve endings are stimulated, sodium enters the nerve ending, which causes 
an electrical signal to build up in the nerve. Once the electrical signal becomes big 
enough, it is able to travel to the brain, which then interprets this as pain. Therefore 
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blocking the initiation and conduction of nerve impulses inhibits depolarization 
of the neuronal membrane [6]. 
Topical anaesthetics with benzocaine are available in creams, ointments, aerosols, 
sprays, lotions and gels. Preparations containing benzocaine and another local aesthetic 
are for example [4]: 
- Wound and burn preparations 
- Sunburn remedies 
- Haemorrhoidal preparations 
- Oral and gingival products 
- Sore throat sprays 
- Callous and wart remedies 
- Creams for treatment of poison ivy 
- Toothache and denture irritation products 
 
A considerable number of publications have appeared describing different strategies 
to quantify benzocaine in tissues and biological fluids of several fish species. Also there 
are papers for the determination of the active in different pharmaceutical dosage forms 
such as tablets, solutions and suspensions, semisolid preparations, suppositories, 
suncreems and after-sun products [7]. 
1.2 BENZOCAINE DEGRADATION PRODUCTS 
p-Nitrobenzoic acid ethylester 
p-Nitrobenzoic acid ethylester or 4-nitrobenzoic acid ethylester (EPNB) is a white 
crystal, slightly soluble in water with formula C9H9NO4 and molar mass 195.175 g/mol. 
p-Nitrobenzoic acid ethylester is not listed in pharmacopoeias [8]. 
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p-Aminobenzoic acid 
p-Aminobenzoic acid, 4-aminobenzoic acid, PABA or vitamin Bx is a white crystalline 
substance, slightly soluble in water with formula C7H7NO2 and molar mass 




PABA is a non-protein amino acid that is widely distributed in nature. It is sometimes 
referred to vitamin B complex (vitamin Bx), but it is neither a vitamin nor an essential 
nutrient for humans. PABA is an intermediate in the synthesis of folic acid in bacteria. 
The sulphonamide antibiotics are structurally similar to PABA and interfere 
with the synthesis of nucleic acids in sensitive microorganisms by blocking 
the conversion of PABA to the co-enzyme dihydrofolic acid, a reduced form of folic 
acid. In humans, dihydrofolic acid is obtained from dietary folic acid; thus 
sulphonamides do not affect human cells [10]. Food sources of PABA are animal meat 
(liver, kidney, etc.), brewer's yeast, molasses, whole grains, mushrooms and spinach, 
and can be made by intestinal bacteria. 
 
PABA is used to improve the protein used in the body, it relates to red blood cell 
formation as well as assisting the manufacture of folic acid in the intestines. 
Furthermore PABA is included in sunscreen preparations since it helps to protect 
the skin from sunburn and cancer (antioxidant) [12]. However, it has been determined 
that it increases the formation of a particular DNA defect in human cells, thus 
increasing the risk of skin cancer in people who lack the mechanisms to repair these 
cellular defects. PABA supplementation may help return gray hair to its original colour 
if the change was caused by either stress or a nutritional deficiency. [11] Pharmaceutical 
doses of PABA are indicated for Peyronie's disease, scleroderma, morphea and linear 
scleroderma [10]. 
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PABA is passively absorbed mainly from the small intestine. From there, it enters 
the portal circulation. Some metabolism of PABA occurs in the liver. A major 
metabolite is N-acetyl PABA. PABA and its metabolites are mainly excreted 
in the urine. Small amounts are eliminated in the feces and in bile, milk 
and other secretions [10]. 
 
When PABA is in short supply fatigue, irritability, nervousness and depression might 
manifest itself as well as constipation. Weeping eczema has also been noted in people 
with PABA deficiency as well as patchy areas on the skin [12]. 
 
Symptoms of high intake were found when higher than factor 8 sunscreens are used; 
the manufacture of vitamin D in the body might be reduced. Nausea, skin rashes 
and vomiting might be indicative of PABA taken in excess. Excessive levels of PABA 
are stored in the body and may cause liver damage [12]. 
1.3 HERPLEX GEL 
Herplex gel produced by Galex d.d., Murska Sobota falls into group of non-prescription 
medicines. These medicines are safe and effective for application without a doctor’s 
prescription and perform considerable part in therapy of ailments as cold and flu, nausea 
or travel sickness, constipation as well as relieve pain, cure of sports injuries, 
musculoskeletal problems, allergies and hay fever and many others. 
 
Herplex is used for treatment of fever blister caused by Herpes simplex virus. Ointment 
provides a soothing effect, as it reduces the sensation of pain and tension of the skin. 
Zinc oxide contained dries up, protects the damaged skin and facilitates its regeneration 
[13]. 
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1.4 ANALYSIS OF BENZOCAINE 
AND ITS DEGRADATION PRODUCTS 
The method for quantification of benzocaine and its degradation products (EPNB 
and PABA) in a bioadhesive gel by HPLC developed by Pérez-Lozano et al. [7] was 
applied for extraction from the Herplex gel. 
 
The validated study was performed with a high-performance liquid chromatographic 
system consisted of a column oven, a quaternary pump, an automatic injector 
and a DAD detector. The DAD detector was set at 258 nm. Data acquisition was made 
out using a chromatography software package. 
 
Chromatographic separation was performed using a Nucleosil 120 C18 column 
250 x 4.6 mm, 10 µm particle size. The mobile phase consisted of methanol 
and solution of glacial acetic acid (10%, v/v) that were carried as a gradient programme 
(Table 1). Both methanol and glacial acetic acid solution were degassed by filtering 
through a 0.45 µm GH-membrane filter. The flow rate was 2.0 ml/min. 
The DAD detector was operated at 258 nm. The injection volume was 10 µl. During 
the analysis the column was equilibrated at 40 ˚C. Each determination required 30 min. 
 
Table 1 
Gradient profile programme to carry out the chromatographic method [7] 
Time (min) Buffer solution (%) Methanol HPLC (%) 
0 90 10 
9 90 10 
13 60 40 
25 60 40 
28 90 10 
30 90 10 
 
Validation parameters as specificity, linearity, intra-day and intermediate precision, 
accuracy and robustness of method were determined. It was checked that benzocaine 
raw material as well as benzocaine reference standard elute at the same retention time 
indicating a positive identification of the drug. All the compounds of the injected 
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sample elute at different retention times and do not interfere between them. Linear 
relationship, with a correlation coefficient higher than 0.9990, was obtained between 
the peak areas of benzocaine at the corresponding concentrations in a range of 70-130% 
of the benzocaine. The factors selected to examine of robustness were the wavelength 
(nm), temperature (˚C), flow rate (ml/min), mobile phase (percentage methanol) 
and volume of injection (µl). It was proved that the selected factors remained unaffected 
by small variations of these parameters. The LOD (LOD for PABA was 5.03 µg/ml 
and for EPNB was 6.06 µg/ml and the LOQ values (LOQ for PABA was 5.03 µg/ml 
and for EPNB was 7.99 µg/ml) for both degradation products EPNB and PABA 
were obtained. 
1.5 VALIDATION OF HPLC METHOD 
Method validation, as an important part of method development, is the process 
ofdemonstrating that analytical procedure is suitable for its intended purpose. Validation 
of a method tests its ability to achieve accuracy, specifity, reliability and precision over 
the specified range that an analyte will be analyzed. 
 
Several guidelines were edited to provide framework and definitions of validation issues 
and requirements for control of the quality of proposed method, e.g.: 
 The US Food and Drug Administration (FDA) [14]: 
Guideline for Submitting Samples and Analytical Data  
for Methods Validation, 
 International Conference on Harmonization (ICH) [15]: 
Validation of Analytical Procedures: Text and Methodology, 
 The US Pharmacopeia (USP) [16]. 
 
The most important analytical procedures that require validation are [15, 16]: 
- Identification tests (Category IV in USP) – analytical methods 
for guaranteed the identity of an analyte in a sample normally achieved 
by comparison of a property of the sample (e.g. spectrum, chemical 
reactivity, etc) to that of a reference standard. 
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- Quantitative and limit tests of impurities (Category II in USP) – analytical 
method for determination of impurities in a sample or degradation 
compounds in finished pharmaceutical products. 
- Assay of active or other ingredients (Category I in USP) – analytical 
methods for quantitative measurement of the major components 
in the drug substance or drug product. 
- (Category III in USP) – analytical methods for determination 
of performance characteristics (e.g. dissolution, drug release) 
 
ICH parameters for validation of analytical procedures are: 




- Precision (Repeatability, Intermediate Precision, Reproducibility) 
- Detection Limit 
- Quantification Limit 
- Robustness 
 
FDA Reviewer Guidance [17] uses additional analytical performance characteristics, 
e.g. recovery, sensitivity and sample solution stability. FDA guideline defines 
the system suitability tests as a required parameter for assay validation. 
 
ICH guidelines treat the system suitability tests as a part of validation parameters 
whereas the USP describes system suitability tests in a separate chapter <621>. 
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Table 2 
ICH and USP validation characteristics [18] 


















































































































* May be required, depending on the nature of the specific test (FDA) 
 
(1) In cases where reproducibility has been performed, intermediate precision is not 
needed 
 
(2) Lack of specifity of one analytical procedure could be compensated by other 
supporting analytical procedure(s) 
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SPECIFICITY 
Specificity (Selectivity) is the ability of an analytical method to differentiate the analyte 
of interest in the presence of all potential sample components [14]. The discrimination 
is evaluated by the comparison of the response of a blank sample without the analyte 
(only matrix, excipient) with the response of a sample containing the analyte 
and with the response of a sample spiked with the analyte, degradation products, 
process impurities, related chemical compounds, synthesis intermediates, etc. 
 
In order to assure the acceptability of specifity studies the analyte is observed under 
various stress conditions such as 0.1 M HCl; 0,1 M NaOH; heat, UV light, oxidant 
(H2O2) and the results are compared. 
LINEARITY 
Linearity verifies that the sample solutions are directly proportional to concentration 
in a concentration range where analyte response is linear [19]. Standard solutions can 
be prepared by a serial dilution of mother solution or by an independent weighing. 
According to ICH guidelines the calibration curve is generated by a minimum 
of 5 concentration levels of the target analyte concentration while FDA recommends 
6-8 non-zero standard solutions (in triplicates). A calibration curve for each analyte 
in the sample is required. 
 
The linearity of analytical method is determined by the linear regression equation (1) 
with the y-intercept (less than a few percent of the response obtained for the analyte 




baxy    (1) 
a slope of the calibration curve (S) 
b y-intercept 
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RANGE 
Range is the interval between the upper and lower levels of analyte (including these 
levels) that have been demonstrated to be determined with precision, accuracy 
and linearity using the method as written [16]. 
 
The range of the analytical method usually depends on an intended purpose 
of the method. Typical ranges for the assay are 80-120% of the target concentration, 
for impurity test the minimum range is from the reporting level of each impurity 
to 120% of the specification [19], +/- 20% over the specified range for dissolution 
testing and 70-130% of the expected concentration for content uniformity testing [15]. 
The range is normally expressed in the same units as the results obtained in the 
linearity study. 
ACCURACY 
Accuracy is the degree of closeness between the true value of analytes in the sample 
and the experimental value determined by the new method [15]. The most common 
approach for an evaluation of accuracy is based on the recovery of known amounts 
of analyte spiked into blank sample. Other approaches use, for example, second existing 
validation method with assessed accuracy or reference material with known value. 
In cases where is impossible to generate a pure sample without the analyte the accuracy 
is performed by addition of known quantities of standard (lyophilized material, etc.). 
 
According to ICH the accuracy should be determined by at least in triplicate at each 
level (80, 100 and 120% of label claim), according to FDA a minimum 
of 5 determinations for at least 3 concentrations (low, medium and high) in the range 
of expected concentrations. For impurity methods, spiked samples are prepared 
in triplicate at 3 levels over a range that covers the expected impurity content 
of the sample [19]. 
 
The accuracy should be proved throughout the same procedure as will be used 
in the final method procedure. It is assessed as a percent recovery (Ri) in relation 
to the known amount of analyte added to the sample (2). 







R  100(%)  (2) 
ic  found or measured concentration 
c0 added concentration 
PRECISION 
The precision is the degree of agreement among a series of measurements obtained from 
multiple sampling of the same homogeneous sample under the prescribed conditions 
[15]. The precision is calculated as standard deviation (S.D.), relative standard deviation 
(R.S.D.) named also coefficient of variation (CV) by using formulas listed below (3, 4 
and 5). Both precision and accuracy can be calculated from the same analytical 
experiments. The acceptance criteria for precision depend much on the type of analysis. 
 
Precision may be divided to these categories [15]: 
- REPEATIBILITY (Intra-day precision) 
Repeatability is the measurements of the sample under the same operating 
conditions over a short interval of time (the same laboratory, analyst, 
equipment). According to ICH samples of 3 different concentrations (low, 
medium and high) at three determinations are used for evaluation or samples 
of 100% concentration at 6 determinations. According to FDA analysis 
of a minimum of 5 determinations at three different concentrations (low, 
medium and high) is recommended and the precision values at each 
concentration should not exceed 15% of the CV for bio analytical procedures. 
But, in general, the claim for the precision is 1-5% of the CV. 
 
- INTERMEDIATE PRECISION 
Intermediate precision evaluates within lab variations and their effects 
to the submitted method. Variations involve using different equipment, analysts, 




 INTRODUCTION  
19 
- REPRODUCIBILITY 
Reproducibility is determined by testing homogeneous samples in multiple 
laboratories (collaborative studies). Reproducibility is not normally part 



































xi individual measurement in a set of measurement 
x  arithmetic mean of the set 





  (5) 
DETECTION LIMIT (LOD) 
The limit of detection is the lowest concentration of analyte in a sample that can be 
detected but not necessarily quatitated as an exact value [15]. It is usually expressed 
as the concentration of analyte in the sample. 
 
The type of procedure influences the determination of LOD. Non-instrumental methods 
detect LOD by visual evaluation (e.g. thin-layer chromatography). These methods 
analyse the samples with known concentration of analyte and establish the minimum 
level at which the analyte can be reliable detected. Instrumental procedures use 
a detection based on signal-to-noise ratio or on the standard deviation (S.D.) 
of the response and the slope (S) of the calibration curve according to the formula (6). 
The S.D. of the response can be determined based on the S.D. of the blank, 
on the R.S.D. of the regression line, or the S.D. of y-intercepts of regression lines. 
A signal-to-noise ratio is comparing of signal of samples with known low amount 
of analyte with signals from the analytical blank samples [15]. Ratio 3:1 or 2:1 is 
generally accepted. It is important to establish the LOD on all instruments, in each 
laboratory to which the method will be transferred. 






  (6) 
S.D. standard deviation of y-intercepts of regression lines 
S slope of the calibration curve 
QUANTIFICATION LIMIT (LOQ) 
The limit of quantification is the lowest level of analyte in a sample that can be 
quantitatively determined with suitable precision and accuracy [15]. The LOQ is 
expressed as the concentration of analyte in the sample. 
 
Determination of LOQ also depends on the procedure. Non-instrumental approach uses 
visual evaluation for the analysis of samples with known concentrations of analyte 
and for establishing the minimum level at which the analyte can be quantified 
with acceptable accuracy and precision. Also signal-to-noise ratio is performed 
for instrumental procedures where ratio should be 10:1. The LOQ may be calculated 





  (7) 
S.D. standard deviation of y-intercepts of regression lines 
S slope of the calibration curve 
ROBUSTNESS 
Robustness of the method investigates its ability to remain unaffected in variations 
in method parameters. Parameters that could be validated are pH of the mobile phase, 
buffer concentration of the mobile phase, percent organic content, flow rate, different 
columns and temperature. 
RUGGEDNESS 
The ruggedness of an analytical method is the degree of reproducibility of test results 
obtained by the analysis of the same samples under a variety of normal test conditions, 
such as different laboratories, different analysts, different instruments, different 
temperature, different days, etc [16]. 
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RECOVERY 
The recovery is amounts of analyte obtained from a blank sample spiked with known 
quantity of standards in matrix compared to the true aqueous sample spiked 
with standards of the same quantity that represent 100% recovery. The recovery should 
be detected by a minimum of 6 determinations for at least 3 concentrations (low, 
medium and high) in a range of expected concentrations [14]. 
SAMPLE SOLUTION STABILITY 
The stability tests of an analyte or stress studies should be provided to demonstrate that 
impurities and degradants from the active ingredient and excipients, the storage 
conditions and the container systems do not interfere with the active ingredient. 
The solutions should be stable enough to allow for delays such as overnight analyses 
using auto samplers. Stability procedures should reflect conditions during actual sample 
handling and analysis [14]. The limits of stability are gained by comparison to freshly 
prepared standards. 
 
Examples of stability tests define in FDA guidelines (at least 3 measurements of each 
of the low and high concentrations): 
- Short-Term Temperature Stability – analysis of stability after thaw at room 
temperature and storing 4-24 hours 
- Long-Term Stability – evaluation of stability after storing at least the time 
between the date of first sample collection and the last sample analysis. 
- Stock Solution Stability – determination of stability of stock solutions after 
storing at room temperature for at least 6 hours. 
- Post-Preparative Stability – assessment of stability in the final extract 
during the expected maximum analysis time. 
- Freeze and Thaw Stability – valuation of stability after three freeze 
and thaw cycles. 
 
Acceptable stability is 2% change in standard or sample response, relative to freshly 
prepared standards for assay methods or 20% change for impurity methods [19]. 
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1.6 SYSTEM SUITABILITY TEST 
System suitability tests (SST) [14, 18, 20] are used to ensure that the complete testing 
system (including instrument, reagents, columns, analysts, etc.) is suitable 
for the intended application and is working properly at the time of analysis. According 
to the ICH and the FDA guidelines, SST is an integral part of analytical procedures 
and should be establish at the beginning part of method validation to assure that 
the HPLC system and procedure are capable of carrying out the analysis 
from the original laboratory to another, on other equivalent equipment, on other days 
or locations. Parameters such as plate count, tailing factors; resolution and repeatability 
are determined. 
 
These parameters are studied by analysis of a system suitability sample that is a mixture 
of main active drug and expected or a known impurity. The reproducibility (%R.S.D.) 














Fig. 1 Definition of terms for system suitability parameters [18] 
Where: Wx width of the peak determined at 5% (0.05) from the baseline  
  of the peak height 
  f distance between peak maximum and peak front at Wx 
  t0 elution time of the void volume or non-retained components 
  tr retention time of the analyte 
  tw peak width measured at baseline of the extrapolated straight  
   sides to baseline 
CAPACITY FACTOR 







  (8) 
tR retention time of the component (min) 
(time measured from time of injection to time of elution of peak maximum) 
t0 elution time of the void (dead) volume or non-retained components (min) 
(time that the solute needs to be transported with mobile phase until gets 
elute time) 
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The peak should be well resolved from other peaks and the void volume, 
generally k' > 2.0. 
NUMBER OF THEORETICAL PLATES 























N RR   (9) 
W width of peak measured at baseline of the extrapolated straight sides 
to the baseline (min) 
W0.5 width of peak at half height (min) 
 
The theoretical plate number depends on elution time but in general should be > 2000. 
RESOLUSION 









  (10) 
t1, 2 retention times of two components (min) 
W1, 2 corresponding widths of the bases of the peaks (min) 
 
Resolution value should be > 2 between the peak of interest and the closest eluting 
potential interferent (impurity, excipient, degradation product, internal standard, etc.). 
TAILING FACTOR 
The accuracy of quantitation decreases with increase in peak tailing T due to improper 





05.0  (11) 
W0.05 width of peak at 5% height (min) 
f distance between peak maximum and peak front at W0.05 (min) 
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Tailing factor ≤ 2 is required for HPLC study. 
REPEATABILITY 
Repeatability expressed as %R.S.D. (12) indicates the agreement of results obtained 



















xi individual measurement in a set of measurement 
x  arithmetic mean of the set 
n number of individual measurements 
 
R.S.D. ≤ 1% for more than 5 measurements is desirable. 
RELATIVE RETENTION 
Relative retention α is a measure of the relative location of two peaks (13). This is not 
















  (13) 
k'1,2 capacity factor of two components peaks 
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2 AIMS OF THE STUDY 
Main aim of the study is quantification of benzocaine and its degradation products 
(p-nitrobenzoic acid ethylester (EPNB) and p-aminobenzoic acid (PABA)) in Herplex 
gel. Method for determination of all three components will be developed following 
existing literature data [7]. 
 
Herplex gel, Galex d.d. containing benzocaine, zinc oxide, white vaseline, liquid 
paraffin, anhydrous lanolin, purified water, maltodextrin, colloidal anhydrous silicon 
dioxide and Melissae extractum siccum will be analysed. 
 
HPLC method will be able to test the most important validation parametres. 
The detection limits and quantification limits will be determined for EPNB and PABA. 
 
HPLC method should allow determining benzocaine, EPNB and PABA 
with no interference with excipients, quantification of benzocaine to ensure that 
the concentration of active substance is within the range 90-110% of the nominal 
concentration, and reliable verification of degradation products presence. 
 
Method will be used also for monitoring of these degradation products during 
manufacturing process and storage of pharmaceuticals with intention to control 
the quality (concentration of degradation products). The quantity of active substance 
in final product is assessed with titration method in the manufacturing process. 





- BENZOCAINE microcrystalline, C9H11NO2, M = 165.19 g/mol, Galex d.d., 
Murska Sobota, Slovenia 
- p-AMINOBENZOIC ACID, C7H7NO2, M = 137.136 g/mol, Fluka, Buchs, 
Sweeden 
- p-NITROBENZOIC ACID ETHYLESTER, C9H9NO4, M = 195.17 g/mol, 
Fluka, Buchs, Sweeden 
3.1.2 Chemicals and reagents 
- METHANOL for liquid chromatography, CH3OH, M = 32.04 g/mol, Merck, 
Darmstadt, Germany 
- ACETIC ACID (glacial) 100 % GR for analysis, CH3COOH, M = 60.05 g/mol, 
Merck, Darmstadt, Germany 
- TETRAHYDROFURAN for liquid chromatography, C4H8O, M = 72.11 g/mol, 
Merck, Darmstadt, Germany 
- DICHLOROMETHANE GR for analysis, CH2Cl2, M = 84.93 g/mol, Merck, 
Darmstadt, Germany 
- HPLC grade WATER, H2O, Katedra za klinično biokemijo, Fakulteta za 
Farmacijo, Univerza v Ljubljani, Slovenia 
- MELISSAE EXTRACTUM siccum, Galex d.d., Murska Soboty, Slovenia 
- ACETONE GR for analysis, CH3COCH3, M = 58.08 g/mol, Merck, Darmstadt, 
Germany 
- DIMETHYL SULFOXIDE CHROMASOLV® for high-performance liquid 
chromatography, C2H6OS, M = 78.13 g/mol, Sigma-Aldrich, Steinheim, 
Germany 
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- BENZYL ALCOHOL GR for analysis, C6H5CH2OH, M = 108.14 g/mol, Merck, 
Darmstadt, Germany 
- 1-PROPANOL for liquid chromatography, CH3CH2CH2OH, M = 60.10 g/mol, 
Merck, Darmstadt, Germany 
- 2-PROPANOL gradient grade for liquid chromatography, CH3CH(OH)CH3, 
M = 60.10 g/mol, Merck, Darmstadt, Germany 
3.1.3 Pharmaceutical products for determination 
- HERPLEX ointment, 15 g, Galex d.d., Murska Sobota, Slovenia 
Herplex gel (15 g) contains 5% of benzocaine (50 mg/g of gel) (Benzocainum), 
Melissae extractum siccum (Melisa officinalis), white vaseline (Vaselinum album), 
liquid paraffin (Paraffinum liquidum), anhydrous lanolin (Adeps lanae), purified water 
(Aqua purificata), maltodextrin, colloidal anhydrous silicon dioxide and zinc oxide 
(100 mg/g of gel) (Zinci oxidum). 
Batches analysed: No 07670904 (expiration 09/2005) 
No 09341105 (expiration 11/2006) 
No 02870306 (expiration 03/2007) 
No 05990706 (expiration 07/2007) 
No 06000706 (expiration 07/2007) 
No 06010706 (expiration 07/2007) 
No 09771206 (expiration 12/2007) – three sample (1, 2, 3) 
No 09781206 (expiration 12/2007) – three sample (1, 2, 3) 
 
- HERPLEX without benzocaine, Galex d.d., Murska Sobota, Slovenia 
Herplex excipient consists of Melissae extractum siccum (Melisa officinalis), white 
vaseline (Vaselinum album), liquid paraffin (Paraffinum liquidum), anhydrous lanolin 
(Adeps lanae), purified water (Aqua purificata), maltodextrin, colloidal anhydrous 
silicon dioxide and zinc oxide (Zinci oxidum). 
Batches analysed: No 02880306 
No 011206 
No 111206 
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3.2 EQUIPMENT 
- Analytical balance AG 245, Mettler Toledo, Columbus, USA 
- Water Polishing System PURELAB® Classic UF, ELGA, UK 
- Ultrasonic cleaner SONIS, Iskra, Sentjernej, Slovenia 
- UV-Visible Spectrophotometer 8453 Hewlett Packard, Agilent Technologies, 
USA 
- Vacuum filtration unit, Sartorius AG, Goettingen, Germany 
- Cellulose acetate filter, 0.45 µm, Sartorius AG, Goettingen, Germany 
- Minisart RC 25 filter, 0.45 µm, Sartorius AG, Goettingen, Germany 
- Filter Paper 388, Sartorius AG, Goettingen, Germany 
- Columns: 
- Eclipse XDB C18 (150 x 4.6 mm, 5 µm), No 993067-902, Agilent 
Technologies, USA 
- Nucleosil 100 C18 (150 x 6.6 mm, 5 µm), No 049891, Agilent Technologies, 
USA 
- HPLC system Agilent 1100 Series, Agilent Technologies, USA: 
- Quaternary pump G1312A 
- Automatic injector 
- Degasser G1379A 
- Column oven G1316A 
- DAD detector G1315A 
- Software package ChemStation for LC3D, Rev. B.01.01 [164] SR1, 2005, 
Agilent Technologies, USA 
3.3 CHROMATOGRAPHIC CONDITIONS 
Two methods for determination of benzocaine and its degradation products were 
developed. The method A was used for determination and quantification of benzocaine 
and EPNB and the second method, the method B, was used for determination 
and quantification of PABA. 
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3.3.1 Chromatographic method A 
Column: Eclipse XDB C18, 150 x 4.6 mm, 5 µm particle size 
Mobile phase: glacial acetic acid solution (10%, v/v) and methanol in a gradient 
programme (Table 3) 
Injection volume: 10 µm 
Flow rate: 2.0 ml/min 
Temperature: 40 ºC 
DAD detector: 258 nm 
Determination time: 30 min 
 
Table 3 
Gradient profile program of method A for benzocaine and EPNB 
Time (min) 
Acetic acid glacial 
(%) 
Methanol (%) 
0 90 10 
9 90 10 
13 60 40 
25 60 40 
28 90 10 
30 90 10 
3.3.2 Chromatographic method B 
Column: Eclipse XDB C18, 150 x 4.6 mm, 5 µm particle size 
Mobile phase: glacial acetic acid solution (10%, v/v) and methanol (90% / 10%) 
Injection volume: 10 µm 
Flow rate: 1.0 ml/min 
Temperature: 40 ºC 
DAD detector: 258 nm 
Determination time: 10 min 
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3.4 PREPARATION OF SOLUTIONS 
3.4.1 Preparation of solutions for UV spectra 
measurement 
Solutions for UV detection were prepared separately for each active. The weighed 
amount of individual active (5.78 mg of benzocaine, 5.21 mg of EPNB and 4.48 mg 
of PABA) was diluted with tetrahydrofuran in a 50 ml volumetric flask. 1 ml 
of the solution was transferred to a 10 ml volumetric flask and it was diluted with THF. 
After that, 5 ml of the solution was placed in a 10 ml volumetric flask and diluted 
with THF. PABA solution had to be diluted again therefore 5 ml of solution was 
transferred to a 10 ml volumetric flask and diluted with THF. The final concentration 
of each active (5.78 µg/ml for benzocaine, 5.21 µg/ml for EPNB and 2.24 µg/ml 
for PABA) gave the absorbance below 1.0 on a spectrophotometer. 
3.4.2 Preparation of mobile phase 
The mobile phase for both methods consists of glacial acetic acid solution (10%, v/v) 
and methanol. Proportion of constituents of mobile phase is influenced by type of used 
method. In method A constituents were carried as a gradient programme (Table 3) 
whereas in method B proportion of compositions is constant, 90% solution of acetic 
acid glacial and 10% of methanol. 
 
Glacial acetic acid solution was prepared by diluting of acetic acid glacial 100% 
with HPLC grade water which was filtrated through a 0.45 µm Cellulose acetate filter 
or filter paper 388. 
3.4.3 Preparation of standard solutions 
a) STANDARD SOLUTIONS FOR LINEARITY DETERMINATION 
Working standard solutions of benzocaine and its two degradation products were 
prepared by dissolving approximately 20 mg of individual active (true amounts are 
listed below) with tetrahydrofuran in 100 ml volumetric flask. Based on this solution 
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and with adequate dilution with glacial acetic acid solution (Table 4 and Table 5), 
6 standard solutions for determination of benzocaine linearity and 10 standard solutions 
for EPNB and PABA were prepared. 
 
For benzocaine linearity we weighed 20.20 mg (samples No 1.1 and No 1.2) 
and 20.20 mg (samples No 2.1 and No 2.2) of benzocaine, 20.04 mg of EPNB (samples 
No 1.1 and No 1.2) and 20.00 mg of EPNB (samples No 2.1 and No 2.2) and 20.10 mg 
of PABA (samples No 1.1 and No 1.2) and 20.00 mg of PABA (samples No 2.1 
and No 2.2). Two working standard solutions were prepared. 
 
Table 4 





Composition of solutions (100 ml) 
1. 200 20 mg benzocaine + THF 
2. 160 80 ml of sol. No 1. + acetic ac. gl. (10%) 
3. 80 50 ml of sol. No 2. + acetic ac. gl. (10%) 
4. 40 50 ml of sol. No 3. + acetic ac. gl. (10%) 
5. 16 40 ml of sol. No 4. + acetic ac. gl. (10%) 
6. 8 50 ml of sol. No 5. + acetic ac. gl. (10%) 
 
Table 5 
Composition of standard solutions for linearity study of degradation products 





Composition of solutions 
Total volume 
(ml) 
1. 200 20 mg EPNB (PABA) + THF 100 
2. 160 80 ml of sol. No 1. + acetic ac. gl. (10%) 100 
3. 80 50 ml of sol. No 2. + acetic ac. gl. (10%) 100 
4. 40 50 ml of sol. No 3. + acetic ac. gl. (10%) 100 
5. 16 40 ml of sol. No 4. + acetic ac. gl. (10%) 100 
6. 8 50 ml of sol. No 5. + acetic ac. gl. (10%) 100 
7. 4 25 ml of sol. No 6. + acetic ac. gl. (10%) 50 
8. 2 25 ml of sol. No 7. + acetic ac. gl. (10%) 50 
9. 1 25 ml of sol. No 8. + acetic ac. gl. (10%) 50 
10. 0.5 25 ml of sol. No 9. + acetic ac. gl. (10%) 50 
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b) MIXING OF EXCIPIENT WITH THE ACTIVE 
Approximately 9.5 g of Herplex excipient was weighed and placed into mortar 
containing 0.5 g of active (as amount of benzocaine in Herplex gel) and mixed 
with pestle. Extraction procedures of active are explained below (method A and B). 
 
Mixtures one of the active (benzocaine, EPNB or PABA) and Herplex excipient were 
prepared and analysed. Precision and accuracy studies of all substances were carried out 
with these mixtures. 
 
Exact amount of individual active, amount of Herplex excipient mixed with individual 




Composition of mixtures of active and excipient for precision and accuracy 
detection 
Active 
Amount of active 
(mg) 
Total amount (mg) 
Amount used for 
test (mg) 
  501,30  10 040,1 1 126,90 
Benzocaine 502,10  10 118,0 969,00 
  501,30  10 103,3 1 063,50 
  500,00  10 038,8 1 130,00 
EPNB 501,70  10 260,7 1 220,90 
  501,80  10 164,0 983,50 
  499,40  10 009,6 1 079,90 
PABA 500,60  9 997,8 1 125,60 
  501,30  10 025,1 1 058,80 
 
Evaluation of method specificity was made on samples of Herplex excipients 
of different age according to method A and B. 
RECOVERY OF BENZOCAINE AND EPNB (METHOD A) 
Approximately 1 g of mixture of either Herplex excipient and benzocaine or Herplex 
excipient and EPNB (which corresponds to 50 mg of active substance content in 1 g 
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of gel) was weighed, placed into a 50.0 ml volumetric flask and was made up 
to the volume with dichloromethane. This mixture was sonicated for 5 min. 
An appropriate amount of solution was filtered through the Minisart RC 25 filter 
(0.45 µm) and parallel samples of 2 ml of solution were prepared. After that, 
the samples were evaporated on a water bath at temperature 50-55 °C. To the rests 5 ml 
of tetrahydrofuran were added. The solutions were again sonicated; 3 ml of solutions 
were transferred into 10 ml volumetric flasks and diluted with glacial acetic acid 
solution (10%, v/v). These solutions were filtered through the Minisart RC 25 filter 
(0.45 µm) and analysed with HPLC. 
RECOVERY OF PABA (METHOD B) 
For study of PABA, approximately 1 g of Herplex excipient and PABA mixture was 
weighed, placed into a 50.0 ml volumetric flask and tetrahydrofuran was added. This 
mixture was sonicated for 5 min. Afterwards an appropriate amount of solution was 
filtered through the Minisart RC 25 filter (0.45 µm). Parallel samples of 2 ml of solution 
were transferred into 25 ml volumetric flasks and diluted with solution of glacial acetic 
acid (10%, v/v). These solutions were filtered through the Minisart RC 25 filter 
(0.45 µm) and analysed with HPLC. 
3.4.4 Preparation of assay samples 
EXTRACTION OF BENZOCAINE AND EPNB FROM GEL (METHOD A) 
For extraction of benzocaine and EPNB, approximately 1 g of topical gel (which 
corresponds to 50 mg of benzocaine) was weighed, placed into a 50.0 ml volumetric 
flask and was made up to the volume with dichloromethane. This mixture was sonicated 
for 5 min. Afterwards an appropriate amount of solution was filtered through 
the Minisart RC 25 filter (0.45 µm). Parallel samples of 2 ml of solution were taken 
and evaporated on a water bath at temperature 50-55 °C. To the rests 5 ml 
of tetrahydrofuran were added. The solutions were again sonicated, 3 ml of solutions 
were transferred into 10 ml volumetric flasks and diluted with glacial acetic acid 
solution (10%, v/v). These solutions were filtered through the Minisart RC 25 filter 
(0.45 µm) and analysed with HPLC. 
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EXTRACTION OF PABA FROM GEL (METHOD B) 
For extraction of PABA, approximately 1 g of topical gel was weighed, placed 
in a 50.0 ml volumetric flask and diluted with tetrahydrofuran. This mixture was 
sonicated for 5 min. and an appropriate amount of solution was filtered through 
a Minisart RC 25 filter (0.45 µm). Parallel samples of 2 ml of solution were prepared 
and transferred into 25 ml volumetric flasks. After that, the solutions were diluted 
with glacial acetic acid solution (10%, v/v). These solutions were filtered through 
the Minisart RC 25 filter (0.45 µm) and analysed with HPLC. 
 















Table 7. For determination were used Herplex gels of all batches mentioned in chapter 
3.1.3. 
 
Amounts of Herplex gels (batch No 09771206, sample 1 and 3) used for thermal 
stability determination are presented in Table 8. The samples (E and F) were prepared 
according the extraction processes (method A and B) described above 


















Herplex gel´s amounts of all batches taken for performing of assay study 
Herplex gel Sample 
Amount of gel (mg) 
Method A Method B 
A A1          1 177,50              1 025,50     
No 07670904 A2          1 164,50              1 068,00     
B B1          1 018,70              1 048,50     
No 02870306 B2          1 091,90              1 087,10     
C C1          1 001,80              1 152,30     
No 09341105 C2          1 051,60              1 053,90     
D D1          1 040,91              1 068,20     
No 06010706 D2          1 003,50              1 050,80     
E E1             992,00              1 030,00     
No 09771206-1 E2          1 063,40              1 137,70     
F F1          1 007,10              1 167,80     
No 09771206-3 F2          1 041,50                        -       
G G1             989,00              1 059,10     
No 09781206-1 G2             931,00                 998,90     
H H1          1 210,90              1 092,40     
No 09781206-3 H2          1 140,80              1 111,40     
I I1             972,20                 917,71     
No 05990706 I2          1 020,60                        -       
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J J1             991,60              1 023,33     
No 06000706 J2          1 037,70                        -       
K K1          1 116,30              1 038,46     
No 06010706 K2          1 120,70                        -       
 
Table 8 
Herplex gel´s amounts (batch No 09771206) taken for thermal stability study 
Herplex gel Sample 
Amount of gel (mg) 
Method A Method B 
E 
E1          1 139,70              1 092,20     
No 09771206-1 
F 
F1             917,70                 942,20     
No 09771206-3 
3.5 HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY 
3.5.1 Development of HPLC conditions 
Chromatography conditions were set up in accordance with the Pérez-Lozano et al. [7] 
method. Two analytical columns were tested. The column Nucleosil 100 C18 
(150 x 6.6 mm, 5 µm) was not successful in flow rate 2 ml/min required for detection 
whereas the column Eclipse XDB C18 (150 x 4.6 mm, 5 µm) allowed detection under 
this condition. 
 
Chromatogram on  
Fig. 2 indicates Herplex excipient mixed with benzocaine, PABA and EPNB obtained 
by method A (chapter 3.3.1). PABA has retention time of 1.095 min and its peak 
interferes with another peak of mobile phase. Therefore another method, method B, 
(chapter 3.3.2) established for determination of PABA has the flow rate 1 ml/min. 








Fig. 2 Chromatogram of Herplex excipient mixed with benzocaine, PABA 
and EPNB analysed by method A (PABA elutes at 1.095, benzocaine at 8.697 
and EPNB at 19.583 min). The peak (retention time 16.172 min) comes from 
the filter paper 388. 
 
The peak with retention time 16.172 min is from the filter paper 388 as is explained 




Fig. 3 Chromatogram of Herplex excipient mixed with PABA analysed by method 
B (PABA elutes at 2.193 min). 
 
Determination and quantification of benzocaine and its degradation products were 
performed by two methods. Method A was used for benzocaine and EPNB 
determination and method B for PABA determination (as described in chapter 3.4.4). 
 
The extraction effectivity of both methods was evaluated by comparison of results 
obtained from extraction of benzocaine and EPNB by method B and extraction 
of PABA by method A with results obtained during validation. 
 
Extraction of PABA by method A was insufficient already during development 
of isolation procedure (chapter 3.5.2) therefore this extraction effectivity was not 
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analysed again. Method B extraction was verified on Herplex gel samples and EPNB 









Table 9 and Table 10. 
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% of benzocaine recovery gained from Herplex gels (batches A-C: No 07670904, 
No 09052006 and No 09341105) according to extraction procedure of method B 
Sample 
Theoretical c of 
BZC (µg/ml) 
Vial No 
Mean of peak 
areas (mAU*s) 




1 708,76 89,10             96,64     
2 718,50 90,31             97,95     
B 88,78 
1 698,69 87,85             98,95     
2 715,35 89,92           101,28     
C 95,74 
1 735,38 92,40             96,51     
2 741,29 93,14             97,28     
 
By extraction of benzocaine with method B, 98.10% of recovery was gained 
(it responds to the guidelines required value 100 ± 5%). 
 
Method B was also examined on mixtures of Herplex excipient and EPNB prepared for 
 EPNB accuracy study (Table 10). Mean value of EPNB recovery obtained was 90.91%, 
which is below 100 ± 5%, and it does not respond to recommended values. Therefore 
method A was used for determination and quantification of benzocaine and EPNB. 
 
Table 10 
Results of EPNB recovery method obtained according to extraction procedure of 
method B 
No  Vial Added c (μg/ml) Found c (μg/ml) Recovery (%) R.S.D. (%) 
1 1.1. 
79,06 
70,84 89,60 0,1771 
2 1.2. 74,14 93,78 0,2244 
3 2.1. 
79,06 
70,34 88,97 0,1523 
4 2.2. 73,48 92,94 0,1272 
5 3.1. 
79,06 
70,06 88,62 0,2009 
6 3.2. 72,37 91,54 0,3766 
3.5.2 Development of isolation procedure for 
benzocaine, EPNB and PABA from gel 
For establishment of this method many analytical procedures (solvents and proportions 
of dilution) were tested. Pérez-Lozano et al. [7] and their validated method has used 
ethanol and adequate dilution for extraction from bioadhesive gel. 
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Different extraction media were used for development of method – acetone, 
methanol (MeOH), ethanol, 1-propanol, 2-propanol, benzyl alcohol, dimethylsulfoxide, 
tetrahydrofuran (THF) and dichloromethane (DCHM). Only last two THF and DCHM 
were effective. 
 
Series of dilutions and measurements (with chromatographic conditions of method A) 
followed. In all cases 50 ml volumetric flask (VF) containing 1 g of mixture (generated 
from 9.5 g of Herplex excipient and 0.5 g of benzocaine) was made up to the volume 
with one of solvents listed below, sonicated and filtered through Minisart RC 25 
filter (0.45 µm). 
Solvents and proportions of dilution, which were analysed: 
1) Solution of tetrahydrofuran in 50 ml volumetric flask and 1 g of mixture. 
Additional dilution: 
a) 10 ml of solution and glacial acetic acid solution in 500 ml VF 
b) 5 ml of solution and glacial acetic acid solution in 10 ml VF 
In both solutions with glacial acetic acid solution 
precipitation occurred. 
c) 5 ml of solution and THF in 50 ml VF 
d) 2 ml of solution and THF in 50 ml VF 
On chromatograms were non-symmetric peaks. 
e) 5 ml of solution and MeOH in 10 ml VF 
f) 5 ml of solution and MeOH in 50ml VF 
g) 5 ml of solution and DCHM in 10 ml VF 
h) 5 ml of solution and DCHM in 25 ml VF 
i) 5 ml of solution and DCHM in 50 ml VF 
Procedures gave benzocaine recovery about 110%. 
2) Solution of dichloromethane in 50 ml volumetric flask and 1 g of mixture. 
Additional dilution: 
a) 5 ml of solution and DCHM in 5 VF 
b) 5 ml of solution and DCHM in 20 VF 
c) 5 ml of solution and DCHM in 50 VF 
Procedures gave benzocaine recovery from 100 - 110%. 
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Since DCHM and acetic acid solution are not miscible next procedures were found 
on evaporation of DCHM. 
d) 2 ml (also 1 ml) of solution was evaporated and 2 ml of THF was 
added, then 1 ml was transferred in 10 ml VF and diluted with THF 
Peak presented on chromatogram was non-symmetric. 
e) 2 ml of solution was evaporated and 2 ml THF was added, then 
1 ml was transferred in 10 ml VF and diluted with acetic acid 
solution 
f) 2 ml of solution was evaporated and 10 ml THF was added, then 
5 ml was transferred in 10 ml VF and diluted with MeOH 
g) 2 ml of solution was evaporated and 10 ml THF was added, then 
5 ml was transferred in 10 ml VF and diluted with acetic acid 
solution 
These samples gave benzocaine recovery in a range  
102 - 105% (with MeOH approximately 105%). 
h) 2 ml of solution was evaporated and 5 ml THF was added, then 
3 ml was transferred in 10 ml VF and made up with acetic acid 
solution 
99.5-103.0% recovery of benzocaine was gained. 
 
Values of benzocaine recovery 100 ± 5% are considered as sufficient. The procedure h) 
was proved on mixture EPNB or PABA with Herplex excipient and recoveries obtained 
were in range 95 - 98% for EPNB and 90 - 93% for PABA. That is why another method 
had to be established for extraction of PABA from Herplex gel. 
3) Solution of dichloromethane in 50 ml volumetric flask and 1 g of mixture 
were sonicated and filtered. Afterwards: 
a) 2 ml of solution was evaporated and 10 ml THF was added. 5 ml 
was transferred in 10 ml VF and made up with acetic acid solution 
b) 2 ml of solution was evaporated and 10 ml THF was added. 8 ml 
was transferred in 10 ml VF and made up with acetic acid solution 
PABA recovery were approximately 95% 
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4) Solution of tetrahydrofuran in 50 ml volumetric flask and 1 g of mixture 
were sonicated and filtered. Afterwards: 
a) 2 ml of solution was diluted in 25 ml VF with acetic acid solution. 
PABA recovery was approximately 100%.  
3.5.3 Validation of HPLC method 
SPECIFICITY 
For specificity study samples of placebo (Herplex excipient), Herplex excipient mixed 
with benzocaine (in concentration which corresponds to Herplex gel) and EPNB 
(in concentration near the concentration of LOQ) were prepared for method A. Samples 
of Herplex excipient, Herplex excipient mixed with PABA (in concentration near 
the concentration of LOQ) were prepared for method B. Each sample was prepared 
throughout the processes described in a part 3.4.3. Chromatograms of Herplex gel 
obtained by method A and B are attached to in specificity study. 
LINEARITY 
Linearity study was performed by measuring of 6 concentration levels (standard 
solutions) of benzocaine (8, 16, 40, 80, 160 and 200 μg/ml) and 10 concentration levels 
(standard solutions) of EPNB and PABA (0.5, 1, 2, 4, 8, 16, 40, 80, 160 and 200 μg/ml) 
prepared according to procedure and in amounts described in chapter 3.4.3. Benzocaine 
linearity and EPNB linearity were carried out using method A and PABA linearity was 
carried out using method B. 
 
Analysis was performed with two pairs of solution (chapter 3.4.3, No 1.1, 1.2 and 2.1, 
2.2) with triplicate injection (4 sets of six, ten concentrations in triplicate respectively) 
for benzocaine, EPNB and PABA individually. 
 
Calibration curve, linear regression equation (y-intercept and slope of the regression 
line) and correlation coefficient were calculated. 
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PRECISION 
Precision was proved on the samples of Herplex excipient and individual active 
mixtures prepared according to processes (method A and B) described in chapter 3.4.3. 
Each active (benzocaine, EPNB and PABA) was prepared in triplicate (3 mixtures of 
benzocaine (1, 2 and 3), EPNB and PABA respectively). From each mixture 2 samples 
were prepared (from mixture 1 vials 1.1, 1.2; from mixture 2 vials 2.1, 2.2 and from 
mixture 3 vials 3.1, 3.2). Every sample was injected and measured three times. 
 
Outcomes of each substance were reported as SD (formula 3) and %R.S.D (formula 4) 
of six samples of 100% concentration, each three times injected. 
ACCURACY 
For accuracy determination the same samples as for precision were used, prepared 
in agreement with chapter 3.4.3. (amounts and procedures). Each active (benzocaine, 
EPNB and PABA) was prepared in triplicate (3 mixtures of benzocaine (1, 2 and 3), 
EPNB and PABA respectively). From each mixture 2 samples were prepared 
(from mixture 1 vials 1.1, 1.2; from mixture 2 vials 2.1, 2.2 and from mixture 3 vials 
3.1, 3.2). Every sample was injected and measured three times. 
 
Method accuracy for benzocaine and its degradation products were evaluated as % 
of recovery (formula 2) and %R.S.D (formula 4). of six samples of 100% concentration, 
each three times injected. 
LOQ and LOD 
These limits were determined based on the S.D. of the y-intercepts of regression line 
and the slope from calibration curve of the mean values (equation 6 and 7) of EPNB 
and PABA. 
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4 RESULTS 
4.1 UV SPECTRA DETECTION 
UV spectra of studied actives were measured to prove that the absorption wavelength 
258 nm used in HPLC method was convenient and effective for quantification 
of benzocaine and its degradation products. 
 
Tetrahydrofuran was employed as a blank sample in all cases and solutions 
of individual compounds were prepared according to procedures stated in chapter 3.4.1. 
4.1.1 Benzocaine 
Maximum of absorption wavelength obtained for benzocaine were 220.0 and 289.0 nm 
(Fig. 4). 
 
Fig. 4 UV spectra of benzocaine solution with concentration 5.78 µg/ml 
4.1.2 p-Nitrobenzoic acid ethylester 
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Fig. 5 UV spectra of EPNB solution with concentration 5.21 µg/ml 
4.1.3 p-Aminobenzoic acid 
Maximum of absorption wavelength obtained for PABA were 221.0 and 284.0 nm 
(Fig. 6). 
 
Fig. 6 UV spectra of PABA solution with concentration 2.24 µg/ml 
 
Although the wavelength of maximum absorbance for benzocaine is 289 nm, the used 
wavelength 258 nm chosen following the validated method of benzocaine analysed 
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of benzocaine. The wavelength 258 nm corresponds to the maximum absorbance 
for EPNB (260 nm). 
4.2 VALIDATION OF ANALYTICAL METHODS 
4.2.1 Benzocaine 
SPECIFICITY 
Method specificity for benzocaine determination was verified by comparison 
of chromatograms of Herplex excipient, Herplex excipient mixed with benzocaine, 
Herplex excipient mixed with benzocaine and EPNB and chromatogram of Herplex gel 
performed by method A. 
 
Chromatogram on  
Fig. 7 was provided from Herplex excipient analysed by method A with acetic acid 




Fig. 7 Chromatogram of Herplex excipient obtained by method A (using Cellulose 
acetate filter) 
 
The Herplex excipient chromatogram ( 
Fig. 8) shows an unknown product (peak), which appeared in Herplex excipients and in 
Herplex gels of all used batches determined by method A. The product has come from 
filter paper 388 used for filtration of glacial acetic acid solution in mobile phase. 
Retention time of this product is in range of 15.320 – 17.043 min. and it was found in 
Herplex gel extracted with method B and analysed with conditions of method A. 
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Fig. 8 Chromatogram of Herplex excipient obtained by method A. Peak has come 
from filter paper 388 used for filtration of glacial acetic acid solution. 
 
Peak appearing at 15.9 min was suspected to come from filter paper 388 ( 
Fig. 9). Change of filter paper and using of Cellulose acetate filter confirmed this 




Fig. 9 Chromatogram of HPLC grade water analysed according to conditions 
of method A (peak of product from filter paper 388) 
 
Benzocaine elutes at 8.594 min. ( 
Fig. 10). It was checked that benzocaine added to excipient as well as benzocaine in 
Herplex gel ( 
Fig. 11) elute at the same retention time. No interfering peaks in the closeness of the 
peak of benzocaine were observed in sample chromatogram. 
 
 




Fig. 10 Chromatogram of Herplex excipient mixed with benzocaine prepared for 




Fig. 11 Chromatogram of Herplex gel obtained by method A using Cellulose 
acetate filter for filtration of glacial acetic acid solution 
 
Chromatograms on  
Fig. 12 and  
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Fig. 12 Chromatogram of Herplex excipient mixed with benzocaine and EPNB 
obtained by method A, acetic acid for mobile phase was filtered through Cellulose 




Fig. 13 Chromatogram of Herplex excipient mixed with benzocaine and EPNB 
analysed by method A with acetic acid solution filtered through filter paper 388 
(retention time: benzocaine 8.825, filter paper product 15.400 and EPNB 
19.607 min) 
LINEARITY 
Linear relationship was determined between the peak area of benzocaine 
and the corresponding concentrations, as shown calibration curve ( 
Fig. 14) of mean peak areas values from obtained results (Table 11). Measured values 
of peak areas were adjusted according to concentrations stated in table. 
 
Table 11 
Values of peak areas and corresponding concentrations for benzocaine linearity; 
solution No 1 (benzocaine weigh 20.20 mg) measured two times (sample No 1.1, 
1.2), solution No 2 (benzocaine weigh 20.20 mg) measured two times (sample 
No 2.1, 2.2).  
Concentration Sample No/Peak area (mAU*s) Mean  
 (μg/ml) 1.1. 1.2. 2.1. 2.2. (mAU*s) 
                8,00              57,27              56,36              57,45              57,26               57,09     
              16,00            125,06            122,96            125,06            125,06              124,53     
              40,00            312,20            308,66            312,54            311,19              311,15     
              80,00            630,08            626,37            633,90            627,45              629,45     
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            160,00         1 275,42         1 263,73         1 300,13         1 291,41           1 282,67     
            200,00         1 606,26         1 574,70                   -                     -                      -       
 



























Fig. 14 Calibration curve of benzocaine given from mean values of peak areas 
obtained by measuring. 
 
The linear regression equation y = 8.0497x – 8.4413 and the correlation coefficient 
R
2
 0.9999 were also calculated from mean values. The correlation coefficient of mean 
values ( 
Fig. 14) as well as each of the correlation coefficients (Table 12) correspond to the 
recommended value R
2
  0.999. 
 
In Table 12 regression equations, y-intercepts and slopes of regression line for each set 
of standard samples are reported. 
 
Table 12 
Equation of each individual measuring of benzocaine linearity 
Sample Equation for calibration curve R
2
 
1.1. y = 8.0481x - 8.5184 1,0000 
1.2. y = 7.9026x - 4.2264 1,0000 
2.1. y = 8.1453x - 8.4737 0,9998 
2.2. y = 8.0596x - 4.9476 0,9997 
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RANGE 
The method was found to be linear in the range 8.0 – 160.0 μg/ml ( 
Fig. 14). These concentrations cover area of approximately 10 - 130% of the test 
concentration of benzocaine. 
 
The concentration 200.0 μg/ml of benzocaine could not be included to the range 
and calculating since the shape of its chromatographic peak was no symmetric. 
PRECISION 
Method precision or repeatability was studied at 100% concentration of benzocaine 
with six samples and triplicate injection of each sample. The results obtained are 
presented in Table 13 and were calculated according to equation of calibration curve 
generated from mean values ( 
Fig. 14). %R.S.D. were below 0.15% in all cases and it was found to be well within 




Results gained for the benzocaine precision 
No  Vial Added c (μg/ml) Found c (μg/ml) S.D. R.S.D. (%) 
1 1.1. 119,83 120,28 0,0685 0,0570 
2 1.2. 119,83 123,38 0,0804 0,0652 
3 2.1. 119,10 116,52 0,1395 0,1197 
4 2.2. 119,10 118,82 0,1026 0,0864 
5 3.1. 119,08 118,00 0,1003 0,0850 
6 3.2. 119,08 119,87 0,1733 0,1446 
ACCURACY 
Determinations of six samples of 100% concentration in triplicate injection have 
established set of results for accuracy of benzocaine (Table 14). These results indicate 
that the method gives recovery from 97.84 – 102.96% (mean value is 100.11%) 
and %R.S.D. below 0.13%. In general recovery 100 ± 5% and R.S.D. < 5% are 
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acceptable. Values of added and found concentrations were arranged for 1 g of mixture 




Accuracy study of benzocaine 
No  Vial Added c (μg/ml) Found c (μg/ml) Recovery (%) R.S.D. (%) 
1 1.1. 119,83 120,28 100,37 0,0476 
2 1.2. 119,83 123,38 102,96 0,0544 
3 2.1. 119,10 116,52 97,84 0,1005 
4 2.2. 119,10 118,82 99,77 0,0725 
5 3.1. 119,08 118,00 99,09 0,0714 
6 3.2. 119,08 119,87 100,66 0,1214 
4.2.2 p-Nitrobenzoic acid ethylester 
SPECIFICITY 
Method specificity was verified by comparison of chromatograms of placebo Herplex 
excipient, Herplex excipient mixed with EPNB and Herplex excipient mixed 
with benzocaine and EPNB performed with method A. 
 
On  
Fig. 15 and  
Fig. 16 are shown chromatograms with and without an unknown product with retention 
time in range of 15.320 – 17.043 min. 
 
In chapter 4.2.1 we have proved that peak is coming from filter paper 388 used 









Fig. 15 Chromatogram of Herplex excipient obtained by method A using Cellulose 




Fig. 16 Chromatogram of Herplex excipient with product from filter paper 388 
obtained by method A 
 
p-Nitrobenzoic acid ethylester elutes at 19.428 min. ( 






Fig. 17 Chromatogram of Herplex excipient mixed with EPNB obtained 
by method A 
 




Fig. 18 Chromatogram of Herplex excipient mixed with benzocaine and EPNB 
in concentration close to LOQ value under the conditions of method A (retention 
time: benzocaine 8.601, filter paper 388 product 15.786 and EPNB 19.519 min) 
LINEARITY 
Linear relationship was provided between the peak area of EPNB and the corresponding 
concentrations, as shown calibration curve ( 
Fig. 19) of mean peak areas values from obtained results (Table 15). Values of peak 
areas were adjusted to concentrations stated in table. 
 
Table 15 
Values of peak areas and corresponding concentrations for EPNB linearity; 
solution No 1 (EPNB weigh 20.04 mg) measured two times (sample No 1.1, 1.2), 
solution No 2 (EPNB weigh 20.00 mg) measured two times (sample No 2.1, 2.2).¨ 
Concentration Sample No/Peak area (mAU*s) Mean 
(μg/ml) 1.1. 1.2. 2.1. 2.2. (mAU*s) 
0,50 0,00 0,00 0,00 0,00 0,00 
1,00 18,45 18,30 17,97 17,83 18,14 
2,00 37,09 36,69 36,67 36,44 36,72 
4,00 74,16 74,00 72,69 72,76 73,40 
8,00 149,09 148,47 145,38 145,72 147,16 
16,00 298,13 296,30 291,07 290,40 293,98 
40,00 744,77 740,61 734,11 727,47 736,74 
80,00 1491,27 1485,20 1479,50 1465,71 1480,42 
160,00 3022,16 2970,55 2981,46 2943,37 2979,38 
200,00 3763,60 3727,40 3734,44 3722,68 3737,03 
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Fig. 19 Calibration curve of EPNB gained from mean values of peak area 
and corresponding concentrations 
 
The linear regression equation y = 18.668x – 4.40554 and the correlation coefficient 
R
2
 1.0000 were also calculated from mean values. In Table 16 regression equations, 
y-intercepts and slopes of the regression line of each set of standard samples are 
reported. The correlation coefficients of each individual measuring as well 
as correlation coefficient of mean values correspond to the recommended 
value R
2
  0.999. 
 
Table 16 
Equation of each set of linearity standard samples of EPNB in the range  
of 1.0 – 200.0 μg/ml 
Sample Equation for calibration curve R² 
1.1. y = 18.846x - 3.5233 1,0000 
1.2. y = 18.614x - 1.5752 1,0000 
2.1. y = 18.072x - 5.2853 1,0000 
2.2. y = 18.542x - 5.8376 0,9999 
 
Equation of calibration curve ( 
Fig. 20) in a range of concentration from 8 to 200 μg/ml of EPNB was applied for 
calculation of precision and accuracy studies. 




Values of peak areas and corresponding concentrations used for calculation 
of EPNB precision and accuracy studies 
Concentration Sample No/Peak area (mAU*s) Mean  
 (μg/ml) 1.1. 1.2. 2.1. 2.2. (mAU*s) 
8,00        143,19            143,34            143,50            143,78              143,45     
16,00        287,10            288,75            287,28            288,09              287,80     
40,00        719,76            720,49            692,07            720,94              713,31     
80,00     1 455,22         1 455,50         1 465,94         1 449,16           1 456,45     
160,00     2 931,78         2 915,02         2 990,19         2 915,01           2 938,00     
200,00     3 724,52         3 692,08         3 809,28         3 691,97           3 729,46     
 




























Fig. 20 Calibration curve of EPNB generated from the mean values of peak areas 
(Table 17) and corresponding concentrations used for precision and accuracy 
studies 
RANGE 
The method was found to be linear in the range 1.0 – 200.0 μg/ml ( 
Fig. 19). These concentrations cover area from LOQ value of EPNB to the 
concentration used for precision and accuracy tests of EPNB. Concentration 0.5 μg/ml 
is below the LOQ value of EPNB and this peak area could not be determined. 
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PRECISION 
Method precision or repeatability was studied at 100% concentration of EPNB with six 
samples and triplicate injection of each sample. The results obtained are presented in  
Table 18 and were calculated according to equation of calibration curve generated from 
mean values ( 
Fig. 20). %R.S.D. were below 0.33% in all cases and it was found to be well within 




Precision results of EPNB calculated according to the equation in  
Fig. 20 
No  Vial Added c (μg/ml) Found c (μg/ml) S.D. R.S.D. (%) 
1 1.1. 119,54 121,51 0,3902 0,3211 
2 1.2. 119,54 124,09 0,2096 0,1689 
3 2.1. 117,35 115,89 0,1612 0,1391 
4 2.2. 117,35 121,21 0,1810 0,1493 
5 3.1. 118,49 114,32 0,3656 0,3198 
6 3.2. 118,49 118,80 0,1643 0,1383 
ACCURACY 
Determinations of six samples of 100% concentration in triplicate injection have 
established set of results for accuracy of EPNB (Table 19). These results indicate that 
the method gives recovery from 96.49 – 103.91% (mean value is 100.71%) 
and %R.S.D. below 0.27%. In general recovery 100 ± 5% and R.S.D. < 5% are 
acceptable. Values of added and found concentrations were arranged for 1 g of mixture 











Accuracy study of EPNB calculated according to the equation in  
Fig. 20 
No  Vial Added c (μg/ml) Found c (μg/ml) Recovery (%) R.S.D. (%) 
1 1.1. 119,54 121,51 101,65 0,2687 
2 1.2. 119,54 124,09 103,81 0,1413 
3 2.1. 117,35 115,89 98,76 0,2663 
4 2.2. 117,35 121,21 103,29 0,1144 
5 3.1. 118,49 114,32 96,49 0,2699 
6 3.2. 118,49 118,80 100,26 0,1167 
LOD and LOQ 
Limit of detection and limit of quantification were evaluated according to formula 
(6 and 7) by means of the standard deviation of the y-intercepts (Table 16) and the slope 
of calibration curve of EPNB ( 
Fig. 19). The LOD and LOQ values found for EPNB were 0.3404 μg/ml 1.0315 μg/ml 
respectively. 
4.2.3 p-Aminobenzoic acid 
SPECIFICITY 
Method specificity was verified by comparison of chromatograms of placebo Herplex 
excipient ( 
Fig. 21) and Herplex excipient mixed with PABA ( 
Fig. 22) and chromatogram of Herplex gel ( 
Fig. 24) performed by method B. 
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Fig. 21 Chromatogram of placebo Herplex excipient obtained by method B 
 
p-Aminobenzoic acid elutes at 2.192 min ( 
Fig. 22) and no interfering peaks in the vicinity of this peak were observed on 
chromatogram of Herplex excipient mixed with PABA ( 






Fig. 22 Chromatogram of Herplex excipient mixed with PABA (concentration close 




Fig. 23 Chromatogram of Herplex excipient mixed with PABA, benzocaine 
and EPNB gained by method B prolonged to 50 min (PABA, benzocaine elute 
at 2.201 and 17.563 min, respectively) 
 
Chromatogram of Herplex gel ( 
Fig. 24) demonstrates peak of benzocaine (retention time 6.412 min), which comes from 
previous injection of sample. Peak is recognized after next injection of Herplex gel 
sample under the conditions of method B. If determination time of method B is 
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prolonged to 50 min peak of benzocaine is identified after first injection in retention 





Fig. 24 Chromatogram of Herplex gel with benzocaine peak from previous 




Fig. 25 Chromatogram of Herplex gel gained under the conditions of method B 
prolonged to 50 min. 
LINEARITY 
Linear relationship was provided between the peak area of PABA 
and the corresponding concentrations, as shown calibration curve ( 
Fig. 26) of mean peak areas values from obtained results (Table 20). Values of peak 
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Table 20 
Values of peak areas and corresponding concentrations for PABA linearity; 
solution No 1 (PABA weigh 20.10 mg) measured two times (sample No 1.1, 1.2), 
solution No 2 (PABA weigh 20.00 mg) measured two times (sample No 2.1, 2.2). 
Concentration Sample No/Peak area (mAU*s) Mean 
(μg/ml) 1.1. 1.2. 2.1. 2.2. (mAU*s) 
                0,50     9,35 9,35 9,92 9,34 9,49 
                1,00     19,13 19,01 19,08 18,77 19,00 
                2,00     37,96 37,93 38,12 37,85 37,97 
                4,00     74,97 75,65 75,34 76,15 75,53 
                8,00     151,71 151,09 150,84 150,57 151,06 
              16,00     300,70 301,27 301,75 301,08 301,20 
              40,00     759,55 753,82 760,65 772,58 761,65 
              80,00     1520,51 1520,64 1525,42 1569,29 1533,96 
            160,00     3045,25 3064,40 3133,30 3188,46 3107,85 
            200,00     3974,09 4000,86 3977,77 4033,69 3996,60 
 






























Fig. 26 Calibration curve of PABA generated from the mean values of peak areas 
and corresponding concentrations 
 
The linear regression equation y = 19.784x – 12.246 and the correlation coefficient 
R
2
 0.9996 were also calculated from mean value. The correlation coefficient of mean 
values as well as correlation coefficients of each individual set of standard samples 
(Table 21) correspond to the recommended value R
2
  0.999. In Table 21 regression 
equations of each sample are reported. 
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Table 21 
Equation of each set of linearity standard samples of PABA in a range  
of 0.5 – 200.0 μg/ml 
Sample Equation for calibration curve R² 
1.1. y = 19.559x - 11.096 0,9993 
1.2. y = 19.687x - 13.566 0,9993 
2.1. y = 19.782x - 12.136 0,9998 
2.2. y = 20.107x - 12.187 0,9999 
 
Equation of calibration curve (Fig. 27) in a range of concentration from 8 to 200 μg/ml 
of PABA was applied for calculation of precision and accuracy studies. 
 
Table 22 
Values of peak areas and corresponding concentrations used for calculation 
of PABA precision and accuracy studies 
Concentration Sample No/Peak area (mAU*s) Mean  
 (μg/ml) 1.1. 1.2. 2.1. 2.2. (mAU*s) 
                8,00            136,14            136,16     140,56 141,44          138,57     
              16,00            273,76            273,58     282,44 284,27          278,51     
              40,00            686,95            685,96     710,78 712,26          698,99     
              80,00         1 377,01         1 377,44     1419,15 1434,12       1 401,93     
            160,00         2 754,88         2 768,25     2862,72 2908,06       2 823,48     
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Fig. 27 Calibration curve of PABA generated from the mean values of peak areas 
(Table 22) and corresponding concentrations used for precision and accuracy 
studies. 
RANGE 
The method was found to be linear in the range of 0.5 – 200.0 μg/ml ( 
Fig. 26). These concentrations cover area from the LOQ value of PABA to the 
concentration used for precision and accuracy tests of PABA. 
PRECISION 
Method precision or repeatability was studied at 100% concentration of PABA with six 
samples and triplicate injection of each sample. The results obtained are presented 
in Table 23 and were calculated according to equation of calibration curve generated 
from mean values. %R.S.D. were below 0.11% in all cases and it was found to be well 
within accepted criteria < 5%. Values of added and found concentrations were arranged 
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Table 23 
Precision results of PABA calculated according to the equation in Fig. 27 
No  Vial Added c (μg/ml) Found c (μg/ml) S.D. R.S.D. (%) 
1 1.1. 79,83 80,03 0,0650 0,0812 
2 1.2. 79,83 81,65 0,0330 0,0404 
3 2.1. 80,11 81,19 0,0791 0,0974 
4 2.2. 80,11 81,78 0,0327 0,0400 
5 3.1. 80,01 80,59 0,0293 0,0364 
6 3.2. 80,01 81,73 0,0825 0,1010 
ACCURACY 
Determinations of six samples of 100% concentration in triplicate injection have 
established set of results for accuracy of PABA (Table 24). These results indicate that 
the method gives recovery from 100.21 – 102.24% (mean value is 101.47% 
and %R.S.D. below 0.13%. In general recovery 100 ± 5% and R.S.D. < 5% are 
acceptable. Values of added and found concentrations were arranged for 1 g of mixture 
and calculated according to equation of calibration curve on Fig. 27. 
 
Table 24 
Accuracy study of PABA calculated according to the equation in Fig. 27 
No  Vial Added c (μg/ml) Found c (μg/ml) Recovery (%) R.S.D. (%) 
1 1.1. 79,83 80,03 100,25 0,1017 
2 1.2. 79,83 81,65 102,28 0,0506 
3 2.1. 80,11 81,19 101,34 0,1216 
4 2.2. 80,11 81,78 102,09 0,0499 
5 3.1. 80,01 80,59 100,73 0,0455 
6 3.2. 80,01 81,73 102,15 0,1262 
LIMIT OF DETECTION 
Limit of detection and limit of quantification were evaluated according to formula 
(6 and 7) by means of the standard deviation of the y-intercepts (Table 21) and the slope 
of calibration curve of PABA ( 
Fig. 26). The LOD and LOQ values found for PABA were 0.1691 μg/ml and 
0.5123 μg/ml, respectively. 
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4.3 EXTRACTION FROM HERPLEX GEL 
The method was examined in the assays of the 11 batches (batches A – K) of Herplex 
gel exposed in 3.1.3. In Table 25 dates of measurement and expiration dates 
of individual batches are presented. 
 
Table 25 
List of batches used for determination 
Sample Batch Expiration Date of measurement 
A No 07670904 09/2005 12/2006 
B No 02870306 03/2007 11/2006 
C No 09341105 11/2006 11/2006 
D No 06010706 07/2007 12/2006 
E No 09771206 12/2007 01/2007 
G No 09781206 12/2007 01/2007 
I No 05990706 07/2007 01/2007 
J No 06000706 07/2007 01/2007 
K No 06010706 07/2007 01/2007 
 
Assay samples for determination were consisted of two samples of each batch (sample 
A1, A2; B1, B2; … till K1, K2). Each of two samples had parallel vials (sample A1 had 
vials No 1 and 2 and so on). Accurately weighed amounts of the individual gels as well 
as the approaches for extraction of gel (method A and method B) are described 
in chapter 3.4.4. All batches were analysed under the conditions of method A 
and method B. 
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Table 26 
% recovery of benzocaine (BZC) from Herplex gels obtained using method A 

















Theoretical c of 
BZC (µg/ml) 
Vial No 
Mean of peak 
areas (mAU*s) 
Measured c of 
BZC (µg/ml) 
% recovery 
A1               141,30     
1            1 082,05                   135,47                 95,87     
2            1 142,03                   142,92               101,15     
A2               139,74     
1            1 104,52                   138,26                 98,94     
2            1 026,36                   128,55                 91,99     
B1               122,24     
1               968,58                   121,37                 99,29     
2               951,50                   119,25                 97,55     
B2               131,03     
1            1 067,88                   133,71               102,05     
2            1 078,52                   135,03               103,06     
C1               120,22     
1               961,79                   120,53               100,26     
2               949,86                   119,05                 99,03     
C2               126,19     
1            1 023,88                   128,24               101,63     
2            1 023,16                   128,15               101,55     
D1               122,20     
1               916,42                   114,89                 94,02     
2               935,91                   117,32                 96,01     
D2               120,42     
1               962,05                   120,56               100,12     
2               973,45                   121,98               101,29     
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E1               119,04     
1               943,63                   118,27                 99,36     
2               944,75                   118,41                 99,47     
E2               127,61     
1            1 023,23                   128,16               100,43     
2            1 037,91                   129,99               101,86     
F1               120,85     
1               956,69                   119,90                 99,21     
2               988,52                   123,85               102,48     
F2               124,98     
1            1 003,65                   125,73               100,60     
2            1 029,43                   128,93               103,16     
G1               118,68     
1               940,14                   117,84                 99,29     
2               951,37                   119,24               100,47     
G2               111,72     
1               889,77                   111,58                 99,88     
2               913,02                   114,47               102,46     
H1               145,31     
1            1 133,50                   141,86                 97,63     
2            1 166,23                   145,93               100,43     
H2               136,90     
1            1 108,00                   138,69               101,31     
2            1 122,61                   140,51               102,64     
I1               116,66     
1               928,93                   116,45                 99,81     
2               941,84                   118,05               101,19     
I2               122,47     
1               999,81                   125,25               102,27     
2            1 007,48                   126,21               103,05     
J1               118,99     
1               917,67                   115,05                 96,69     
2               934,43                   117,13                 98,44     
J2               124,52     
1               987,98                   123,78                 99,41     
2               998,36                   125,07               100,44     
K1               133,96     
1               983,56                   123,23                 92,00     
2            1 062,39                   133,03                 99,31     
K2               134,48     
1            1 030,71                   129,09                 95,99     
2            1 073,29                   134,38                 99,92     
Table of reports (Table 26) indicates amount of recovery of benzocaine from Herplex 
gels (method A). All examined batches contain benzocaine in a range               
of 91.99 - 103.16% of label value. The mean value of recovery was 99.61% (calculated 
from results of all batches). 
USP 22 recommends content of not less than 90.0% and not more than 110.0% 
of the labelled amount of benzocaine in benzocaine ointments and creams. 
 
None of the samples (batches) has contained evaluated degradation products 
EPNB or PABA. 
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4.4 THERMAL STABILITY OF HERPLEX GEL 
Thermal stability study of Herplex gel was performed by comparison of results obtained 
from Herplex gel batch No 09771206, sample 1 and 3 (E1 and F1 respectively) stored 
at different temperature for 7 days. 
 
Amount of Herplex gel used for stability study is stated in chapter 3.4.4 as well 
as extraction procedures for benzocaine and EPNB (method A) and PABA (method B). 
Sample E1 was stored at room temperature for 7 days and sample F1 was stored 
at temperature 100 ˚C for 7 days. 
 
Table 27 shows the results obtained by using method A for extraction of benzocaine and 
EPNB. After 7 days at temperature 100 ˚C degradation product EPNB was not found 
in the sample. However by increasing temperature at 100 ˚C was evoked decrease 





% benzocaine recovery results of thermal stability study of Herplex gel (batch 
No 09771206) after 7 days, established by method A (sample E1 stored at room 
temperature and sample F1 stored at temperature 100 ˚C) 
Sample 
Theoretical c of 
BZC (µg/ml) 
Vial No 
Mean of peak 
areas (mAU*s) 
Measured c of 
BZC (µg/ml) 
% recovery 
E1               136,76     
1            1 033,35                   129,42                 94,63     
2            1 028,46                   128,81                 94,19     
F1               110,12     
1               476,73                     60,27                 54,73     
2               498,18                     62,94                 57,15     
 
By performance of PABA extraction (method B) was established that after 7 days 
at temperature 100 ˚C degradation product PABA has appeared in a Herplex gel 
in concentration approximately 0.92 µg/ml (Table 28) calculated according to equation 
in Fig. 27. 
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Table 28 
Results of thermal stability study of Herplex gel (batch No 09771206) after 7 days, 
established by method B (sample E1 stored at temperature 25 ˚C and sample F1 
stored at temperature 100 ˚C) 
Sample Vial No 
Mean of peak 
areas (mAU*s) 
Measured c of 
PABA (µg/ml) 
E1 
1                      -                            -       
2                      -                            -       
F1 
1                  5,89                      0,92     
2                  5,71                      0,91     
4.5 DEGRADATION OF BENZOCAINE 
Calculation of benzocaine amount, which has to be degraded for determination 
of its degradation products EPNB and PABA was establish according to formula (14). 
M
m
n   (14) 
n chemical amount (mol) 
m total mass (g) 
M molar mass (g/mol) 
  MBZC = 165.192 g/mol 
  MEPNB = 195.175 g/mol 
  MPABA = 137.138 g/mol 
 
It was calculated that 1 mol of benzocaine degrades to 1 mol of its degradation product 
(EPNB or PABA). For determination of 1.0315 µg/ml EPNB (LOQ value of EPNB 
obtained before) 0.8730 µg/ml benzocaine has to be degraded. It responds      
3.6375*10
-3
 µg benzocaine contained in 1 g of Herplex gel. And for determination 
of 0.5123 µg/ml PABA (LOQ value of PABA obtained before) 0.6171 µg/ml 
benzocaine has to be degraded. It responds 3.8569*10
-4
 µg benzocaine contained in 1 g 
of Herplex gel. 
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5 CONCLUSION 
It was established the new HPLC method for determination and quantification 
of benzocaine and its two degradation products, p-nitrobenzoic acid ethylester 
and p-aminobenzoic acid, in Herplex gel. 
 
The new HPLC method is consisted of two procedures (A and B) for extraction 
and determination of individual substances of gel since conditions and extraction 
procedure of benzocaine and EPNB is not sufficiently effective for quantification 
of PABA. 
 
The determination was performed with HPLC system Agilent 1100 Series, Agilent 
Technologies and with the column Eclipse XDB – C 18 (150 x 4.6 mm, 5 µm). 
The mobile phase consisted of a mixture of methanol and glacial acetic acid solution 
(10%, v/v) at different proportion according to a time-schedule programme (procedure 
A for benzocaine and EPNB) and at proportion 10% of methanol: 90% of glacial acetic 
acid solution (procedure B for PABA), pumped at a flow rate of 2.0 ml/min 
and 1.0 ml/min respectively. The DAD detector was set at 258 nm. Determination time 
was 30 min and 10 min respectively. Injection volume was 10 µm and thermostat was 
equilibrated at 40 ºC. 
 
The HPLC method has been evaluated over the linearity, precision, accuracy 
and specificity. The UV spectra detection was measured too. The linearity was 
determined with the range of benzocaine concentration 8 - 160 µg/ml and                 
0.5 – 200.0 µg/ml of EPNB and PABA concentration and with the correlation 
coefficient higher than 0.9990 for individual substances. Results of precision 
and accuracy tests (%recovery and R.S.D.) of all substances were bellow the acceptable 
value 5%. The LOD value was 0.3404 µg/ml and the LOQ value was 1.0315 µg/ml 
for EPNB and for PABA 0.1691 µg/ml and 0.5123 µg/ml respectively. 
 
For extraction from gel 9 batches of Herplex gel with different ages were used. All 
examined batches contained benzocaine in a range of 91.99 – 103.16% of label value. 
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In thermal stability study was found that content of benzocaine in Herplex gel fell after 
7 days at temperature 100 ºC to 50% of label value and PABA has appeared in Herplex 
gel in concentration approximately 0.92 µg/m. 
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